Shares of Editas Medicine (NASDAQ: EDIT) were up 12.7% this week, as of Thursday's close, according to data provided by S&P Global Market Intelligence. It did so to improve its cash position, which as of the third quarter was listed at $478.5 million, enabling it to fund operations through 2025. The move further helps Editas' cash position and allows it to focus on its in-vivo gene-editing programs and promising blood therapies, including EDIT-301, used to treat transfusion-dependent beta thalassemia and sickle cell disease.